Jacobs & Co. CA Has $7.91 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Jacobs & Co. CA boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,206 shares of the medical research company's stock after purchasing an additional 1,473 shares during the quarter. Jacobs & Co. CA's holdings in Thermo Fisher Scientific were worth $7,910,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. MGO One Seven LLC lifted its holdings in Thermo Fisher Scientific by 3.1% in the second quarter. MGO One Seven LLC now owns 3,612 shares of the medical research company's stock worth $1,997,000 after purchasing an additional 110 shares during the period. LPL Financial LLC lifted its stake in shares of Thermo Fisher Scientific by 4.6% in the 2nd quarter. LPL Financial LLC now owns 217,770 shares of the medical research company's stock worth $120,427,000 after acquiring an additional 9,578 shares during the period. Qsemble Capital Management LP acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $2,219,000. Johnson Investment Counsel Inc. raised its holdings in Thermo Fisher Scientific by 3.4% during the second quarter. Johnson Investment Counsel Inc. now owns 9,359 shares of the medical research company's stock worth $5,176,000 after purchasing an additional 309 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in Thermo Fisher Scientific by 0.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 31,433 shares of the medical research company's stock valued at $17,382,000 after purchasing an additional 144 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last three months. Corporate insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 23rd. They set a "sector perform" rating and a $605.00 price objective for the company. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Bank of America decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Finally, Stephens began coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price objective for the company. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $650.52.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of NYSE:TMO traded down $1.96 during midday trading on Friday, hitting $542.97. 2,919,946 shares of the stock were exchanged, compared to its average volume of 1,985,240. The business's fifty day simple moving average is $529.91 and its two-hundred day simple moving average is $567.91. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a market capitalization of $207.69 billion, a PE ratio of 34.04, a P/E/G ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.69 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.